These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30049045)

  • 1. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance.
    Noch EK; Ramakrishna R; Magge R
    World Neurosurg; 2018 Aug; 116():505-517. PubMed ID: 30049045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omics sciences and precision medicine in glioblastoma.
    Micheletti C; Bonetti G; Madeo G; Gadler M; Benedetti S; Guerri G; Cristofoli F; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Manganotti P; Caruso P; Bernini A; Fulcheri E; Stuppia L; Gatta V; Cecchin S; Marceddu G; Bertelli M
    Clin Ter; 2023; 174(Suppl 2(6)):77-84. PubMed ID: 37994751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
    Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
    Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of immunotherapy resistance: lessons from glioblastoma.
    Jackson CM; Choi J; Lim M
    Nat Immunol; 2019 Sep; 20(9):1100-1109. PubMed ID: 31358997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
    Kim HJ; Kim DY
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
    Eder K; Kalman B
    Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for glioblastoma.
    Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
    JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
    Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
    Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
    Murat A; Migliavacca E; Gorlia T; Lambiv WL; Shay T; Hamou MF; de Tribolet N; Regli L; Wick W; Kouwenhoven MC; Hainfellner JA; Heppner FL; Dietrich PY; Zimmer Y; Cairncross JG; Janzer RC; Domany E; Delorenzi M; Stupp R; Hegi ME
    J Clin Oncol; 2008 Jun; 26(18):3015-24. PubMed ID: 18565887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
    Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO
    J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.
    Verduin M; Compter I; Steijvers D; Postma AA; Eekers DBP; Anten MM; Ackermans L; Ter Laan M; Leijenaar RTH; van de Weijer T; Tjan-Heijnen VCG; Hoeben A; Vooijs M
    Dis Markers; 2018; 2018():2908609. PubMed ID: 29581794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
    Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
    Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy for brain tumors: obstacles and perspectives].
    Migliorini D; Dietrich PY
    Rev Med Suisse; 2016 Apr; 12(516):828-31. PubMed ID: 27281940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
    Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
    Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
    Abdul KU; Houweling M; Svensson F; Narayan RS; Cornelissen FMG; Küçükosmanoglu A; Metzakopian E; Watts C; Bailey D; Wurdinger T; Westerman BA
    Drug Resist Updat; 2018 Sep; 40():17-24. PubMed ID: 30439622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One size should not fit all: advancing toward personalized glioblastoma therapy.
    Reardon DA; Ligon KL; Chiocca EA; Wen PY
    Discov Med; 2015 Jun; 19(107):471-7. PubMed ID: 26175405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.